301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors. (September 2015) - Azaro, A.; Rodon, J.; Herranz, M.; Nuciforo, P.; Prudkin, L.; Lopez-Busto, N.; Balandraud, S.; Cattan, V.; Jacquet-Bescond, A.; Marfai, L.; Pauly, J.; Postel-Vinay, S.; et al.